Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2017-08-12 Major Shareholding Noti…
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G
Major Shareholding Notification
2017-08-12 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated August 2, 2017, from Pacira Pharmaceuticals, Inc. It specifically references the announcement of results for the second quarter ended June 30, 2017, and includes a press release as Exhibit 99.1. The text states that the press release is furnished as an exhibit and is an announcement of earnings results, not the full earnings report itself. The document length is 3302 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. The key phrase 'we issued a press release announcing our results' and the inclusion of the press release as an exhibit indicate this is an Earnings Release (ER) filing, which is the initial announcement of quarterly financial results with key highlights only, not a comprehensive interim report or annual report. Therefore, the correct classification is Earnings Release (ER).
2017-08-02 English
FORM 4 SUBMISSION
Director's Dealing
2017-07-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's decision to discontinue production of a product line and the associated financial impact, including charges and impairments. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The document is a regulatory filing reporting a material event, fitting the category of Regulatory Filings (RNS). The document length is 3564 characters, which is relatively short and consistent with an 8-K current report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-06-29 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.